These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28277090)

  • 21. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi OG; Loeb M; Coleman BL; Li Y;
    Vaccine; 2012 Jul; 30(32):4728-32. PubMed ID: 22652402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine.
    George VK; Pallikkuth S; Parmigiani A; Alcaide M; Fischl M; Arheart KL; Pahwa S
    J Infect Dis; 2015 Jun; 211(12):1959-68. PubMed ID: 25556252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of prior influenza vaccination on antibody and B-cell responses.
    Sasaki S; He XS; Holmes TH; Dekker CL; Kemble GW; Arvin AM; Greenberg HB
    PLoS One; 2008 Aug; 3(8):e2975. PubMed ID: 18714352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation.
    Parmigiani A; Alcaide ML; Freguja R; Pallikkuth S; Frasca D; Fischl MA; Pahwa S
    PLoS One; 2013; 8(11):e79816. PubMed ID: 24236161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
    Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Artificial Intelligence Applied to
    Cotugno N; Santilli V; Pascucci GR; Manno EC; De Armas L; Pallikkuth S; Deodati A; Amodio D; Zangari P; Zicari S; Ruggiero A; Fortin M; Bromley C; Pahwa R; Rossi P; Pahwa S; Palma P
    Front Immunol; 2020; 11():559590. PubMed ID: 33123133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly.
    Xie H; Jing X; Li X; Lin Z; Plant E; Zoueva O; Yang H; Ye Z
    PLoS One; 2011 Jan; 6(1):e16650. PubMed ID: 21304946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals.
    Chawansuntati K; Chotirosniramit N; Sugandhavesa P; Aurpibul L; Thetket S; Kosashunhanan N; Supindham T; Kaewthip O; Sroysuwan P; Sirisanthana T; Suparatpinyo K; Wipasa J
    Hum Vaccin Immunother; 2015; 11(9):2253-65. PubMed ID: 26091502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study.
    Sundaram ME; Meydani SN; Vandermause M; Shay DK; Coleman LA
    Nutr Res; 2014 Feb; 34(2):149-54. PubMed ID: 24461316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.
    DiazGranados CA; Dunning AJ; Jordanov E; Landolfi V; Denis M; Talbot HK
    Vaccine; 2013 Jan; 31(6):861-6. PubMed ID: 23261045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
    Skowronski DM; Janjua NZ; De Serres G; Purych D; Gilca V; Scheifele DW; Dionne M; Sabaiduc S; Gardy JL; Li G; Bastien N; Petric M; Boivin G; Li Y
    J Infect Dis; 2012 Dec; 206(12):1852-61. PubMed ID: 22872731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term seroprotective response of trivalent seasonal influenza vaccine in HIV-infected children, regardless of immunogenicity before immunisation.
    Moolasart V; Manosuthi W; Ausavapipit J; Chottanapund S; Likanonsakul S; Uttayamakul S; Srisopha S; Lerdsamran H; Puthavathana P
    Int J STD AIDS; 2016 Aug; 27(9):761-8. PubMed ID: 26138900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.
    Ambati A; Einarsdottir S; Magalhaes I; Poiret T; Bodenstein R; LeBlanc K; Brune M; Maeurer M; Ljungman P
    Transpl Infect Dis; 2015 Jun; 17(3):371-9. PubMed ID: 25817044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of aging and HIV infection on serologic response to seasonal influenza vaccination.
    Pallikkuth S; De Armas LR; Pahwa R; Rinaldi S; George VK; Sanchez CM; Pan L; Dickinson G; Rodriguez A; Fischl M; Alcaide M; Pahwa S
    AIDS; 2018 Jun; 32(9):1085-1094. PubMed ID: 29424779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
    Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.